ArticleCase reports in medicine2026
Rivaroxaban and Piperacillin-Tazobactam: Case of Massive Gastrointestinal Bleeding.
Article in Case reports in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rivaroxaban and Piperacillin-Tazobactam: Case of Massive Gastrointestinal Bleeding.Case reports in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticoagulated patients are at increased risk of complications from drug interactions, including with antibiotics. Piperacillin-tazobactam (PTZ) has been associated with coagulation disruptions, potentially leading to severe bleeding when combined with anticoagulants like rivaroxaban. This report describes the first known case of massive gastrointestinal (GI) bleeding potentially associated with PTZ in a rivaroxaban-treated patient, successfully managed by discontinuing both drugs. We present a 52-year-old male with deep vein thrombosis on rivaroxaban, admitted for severe left leg cellulitis. Shortly after starting PTZ, he experienced massive GI bleeding with hematochezia, hematemesis, and syncope, requiring urgent intervention, cessation of both medications, and esophagogastroduodenoscopy (EGD), which revealed minor erosions. The temporal relationship suggests a possible PTZ-induced hemostasis disruption or interaction with rivaroxaban. This case highlights the need for research into PTZ-anticoagulant interactions and emphasizes vigilant monitoring and timely management to reduce life-threatening bleeding risks in anticoagulated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.